3176 Stock Overview
Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Medigen Biotechnology Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$39.10 |
52 Week High | NT$62.40 |
52 Week Low | NT$30.30 |
Beta | 0.62 |
1 Month Change | -7.67% |
3 Month Change | -12.72% |
1 Year Change | 20.68% |
3 Year Change | -40.12% |
5 Year Change | -35.90% |
Change since IPO | 104.71% |
Recent News & Updates
Shareholder Returns
3176 | TW Biotechs | TW Market | |
---|---|---|---|
7D | 2.6% | 1.2% | -0.3% |
1Y | 20.7% | -20.4% | 25.8% |
Return vs Industry: 3176 exceeded the TW Biotechs industry which returned -21.1% over the past year.
Return vs Market: 3176 underperformed the TW Market which returned 26.7% over the past year.
Price Volatility
3176 volatility | |
---|---|
3176 Average Weekly Movement | 4.9% |
Biotechs Industry Average Movement | 4.3% |
Market Average Movement | 4.2% |
10% most volatile stocks in TW Market | 8.1% |
10% least volatile stocks in TW Market | 1.9% |
Stable Share Price: 3176 has not had significant price volatility in the past 3 months.
Volatility Over Time: 3176's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | n/a | Shun-Lang Chang | https://www.medigen.com.tw |
Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States.
Medigen Biotechnology Corp. Fundamentals Summary
3176 fundamental statistics | |
---|---|
Market cap | NT$5.45b |
Earnings (TTM) | -NT$561.30m |
Revenue (TTM) | NT$1.16b |
4.7x
P/S Ratio-9.7x
P/E RatioIs 3176 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
3176 income statement (TTM) | |
---|---|
Revenue | NT$1.16b |
Cost of Revenue | NT$540.39m |
Gross Profit | NT$617.33m |
Other Expenses | NT$1.18b |
Earnings | -NT$561.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -4.03 |
Gross Margin | 53.32% |
Net Profit Margin | -48.48% |
Debt/Equity Ratio | 51.6% |
How did 3176 perform over the long term?
See historical performance and comparison